What is Palvella Therapeutics's G&A?

Palvella Therapeutics (PVLA) reported G&A of $5.52M in Q1 2026.

How has Palvella Therapeutics's G&A changed year-over-year?

Palvella Therapeutics's G&A increased by 45.4% year-over-year, from $3.8M to $5.52M.

What is the long-term trend for Palvella Therapeutics's G&A?

Over 2 years (2021 to 2025), Palvella Therapeutics's G&A has grown at a -2.5% compound annual growth rate (CAGR), from $16.59M to $15.76M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Palvella Therapeutics PVLA G&A

G&A at other companies

Relay Therapeutics, Inc.RLAY

$11.03M-41.2%

Kodiak Sciences IncKOD

$11.23M-27.2%

Ligand PharmaceuticalsLGND

$20.84M+10.8%

Viking TherapeuticsVKTX

$13.98M-0.7%

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's G&A?: Palvella Therapeutics (PVLA) reported G&A of $5.52M in Q1 2026.
How has Palvella Therapeutics's G&A changed year-over-year?: Palvella Therapeutics's G&A increased by 45.4% year-over-year, from $3.8M to $5.52M.
What is the long-term trend for Palvella Therapeutics's G&A?: Over 2 years (2021 to 2025), Palvella Therapeutics's G&A has grown at a -2.5% compound annual growth rate (CAGR), from $16.59M to $15.76M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.